Fulya Bakilan1, Onur Armagan2, Merih Ozgen2, Funda Tascioglu2, Ozge Bolluk3, Ozkan Alatas4. 1. Department of Physical Medicine and Rehabilitation of Yerkoy/Yozgat Public Hospital, Yozgat, Turkey. 2. Department of Physical Medicine and Rehabilitation, Eskişehir Osmangazi University School of Medicine, Eskişehir, Turkey. 3. Department of Biostatistics, Eskişehir Osmangazi University School of Medicine, Eskişehir, Turkey. 4. Department of Biochemistry, Eskişehir Osmangazi University School of Medicine, Eskişehir, Turkey.
Abstract
OBJECTIVE: The aim of this randomized controlled study was to evaluate the efficacy of oral native type II collagen treatment on the symptoms and biological markers of cartilage degradation, when given concomitantly with acetaminophen in patients with knee osteoarthritis. MATERIALS AND METHODS:Thirty-nine patients diagnosed with knee osteoarthritis were included and randomly distributed into two groups: one treated with 1500 mg/day of acetaminophen (group AC; n=19) and the other treated with 1500 mg/day of acetaminophen plus 10 mg/day of native type II collagen (group AC+CII; n=20) for 3 months. Visual Analogue Scale (VAS) at rest and during walking, Western Ontario McMaster (WOMAC) pain, WOMAC function, and Short Form-36 (SF-36) scores, were recorded. Coll2-1, Coll2-1NO2 and Fibulin-3 levels were quantified in urine as biomarkers of disease progression. ClinicalTrials.gov: NCT02237989. RESULTS: After 3 months of treatment, significant improvements compared to baseline were reported in joint pain (VAS walking), function (WOMAC) and quality of life (SF-36) in the AC+CII group, while only improvements in some subscales of the SF-36 survey and VAS walking were detected in the AC group. Comparisons between the groups revealed a significant difference in VAS walking score in favour of the AC+CII group as compared to AC group. Biochemical markers of cartilage degradation in urine did not significantly improve in any of the groups. CONCLUSION: All in all, these results suggest that native type II collagen treatment combined with acetaminophen is superior to only acetaminophen for symptomatic treatment of patients with knee osteoarthritis.
RCT Entities:
OBJECTIVE: The aim of this randomized controlled study was to evaluate the efficacy of oral native type II collagen treatment on the symptoms and biological markers of cartilage degradation, when given concomitantly with acetaminophen in patients with knee osteoarthritis. MATERIALS AND METHODS: Thirty-nine patients diagnosed with knee osteoarthritis were included and randomly distributed into two groups: one treated with 1500 mg/day of acetaminophen (group AC; n=19) and the other treated with 1500 mg/day of acetaminophen plus 10 mg/day of native type II collagen (group AC+CII; n=20) for 3 months. Visual Analogue Scale (VAS) at rest and during walking, Western Ontario McMaster (WOMAC) pain, WOMAC function, and Short Form-36 (SF-36) scores, were recorded. Coll2-1, Coll2-1NO2 and Fibulin-3 levels were quantified in urine as biomarkers of disease progression. ClinicalTrials.gov: NCT02237989. RESULTS: After 3 months of treatment, significant improvements compared to baseline were reported in joint pain (VAS walking), function (WOMAC) and quality of life (SF-36) in the AC+CII group, while only improvements in some subscales of the SF-36 survey and VAS walking were detected in the AC group. Comparisons between the groups revealed a significant difference in VAS walking score in favour of the AC+CII group as compared to AC group. Biochemical markers of cartilage degradation in urine did not significantly improve in any of the groups. CONCLUSION: All in all, these results suggest that native type II collagen treatment combined with acetaminophen is superior to only acetaminophen for symptomatic treatment of patients with knee osteoarthritis.
Entities:
Keywords:
Acetaminophen; knee osteoarthritis; native type II collagen
Authors: S F Ausar; D M Beltramo; L F Castagna; S Quintana; E Silvera; G Kalayan; M Revigliono; C A Landa; I D Bianco Journal: Rheumatol Int Date: 2001-05 Impact factor: 2.631
Authors: M L Barnett; J M Kremer; E W St Clair; D O Clegg; D Furst; M Weisman; M J Fletcher; S Chasan-Taber; E Finger; A Morales; C H Le; D E Trentham Journal: Arthritis Rheum Date: 1998-02
Authors: Karel Pavelká; Jindriska Gatterová; Marta Olejarová; Stanislav Machacek; Giampaolo Giacovelli; Lucio C Rovati Journal: Arch Intern Med Date: 2002-10-14
Authors: J Y Reginster; R Deroisy; L C Rovati; R L Lee; E Lejeune; O Bruyere; G Giacovelli; Y Henrotin; J E Dacre; C Gossett Journal: Lancet Date: 2001-01-27 Impact factor: 79.321
Authors: M Deberg; J-E Dubuc; A Labasse; C Sanchez; E Quettier; A Bosseloir; J-M Crielaard; Y Henrotin Journal: Ann Rheum Dis Date: 2007-07-20 Impact factor: 19.103
Authors: David C Crowley; Francis C Lau; Prachi Sharma; Malkanthi Evans; Najla Guthrie; Manashi Bagchi; Debasis Bagchi; Dipak K Dey; Siba P Raychaudhuri Journal: Int J Med Sci Date: 2009-10-09 Impact factor: 3.738
Authors: Kazim Sahin; Osman Kucuk; Cemal Orhan; Mehmet Tuzcu; Ali Said Durmus; Ibrahim Hanifi Ozercan; Nurhan Sahin; Vijaya Juturu Journal: Sci Rep Date: 2021-07-19 Impact factor: 4.379